FAPi-PET imaging of in vivo early fistula healing in perianal Crohn’s disease: PERSIST study

Conditions

perianal Crohn's fistula

Brief summary

- Visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline, at follow-up (T1) and the change over both time points

Detailed description

- The best fitting kinetic model to quantify 68Ga-FAPi-46 pharmacokinetics and tracer uptake., - The most suitable simplified quantitative measurement as a surrogate for the full kinetic model., - The most simplified imaging procedure providing the quantitative measurement correlating to the full kinetic model., - Correlate visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline, at follow-up (week 2 or week 6 or combined) and the change over both time points with clinical and/or radiological response assessments mid- and end-of-treatment (i.e. week 9 and week 26, respectively)., - Correlate visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline with clinical and MRI (and eventual endoscopy and pathology if available) parameters at baseline.

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGGALLIUM (68GA) CHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
- Visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline, at follow-up (T1) and the change over both time points	—

Secondary

Measure	Time frame
- The best fitting kinetic model to quantify 68Ga-FAPi-46 pharmacokinetics and tracer uptake., - The most suitable simplified quantitative measurement as a surrogate for the full kinetic model., - The most simplified imaging procedure providing the quantitative measurement correlating to the full kinetic model., - Correlate visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline, at follow-up (week 2 or week 6 or combined) and the change over both time points with clinical and/or radiological response assessments mid- and end-of-treatment (i.e. week 9 and week 26, respectively)., - Correlate visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline with clinical and MRI (and eventual endoscopy and pathology if available) parameters at baseline.	—

Measure

Time frame

- The best fitting kinetic model to quantify 68Ga-FAPi-46 pharmacokinetics and tracer uptake., - The most suitable simplified quantitative measurement as a surrogate for the full kinetic model., - The most simplified imaging procedure providing the quantitative measurement correlating to the full kinetic model., - Correlate visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline, at follow-up (week 2 or week 6 or combined) and the change over both time points with clinical and/or radiological response assessments mid- and end-of-treatment (i.e. week 9 and week 26, respectively)., - Correlate visual and quantitative 68Ga-FAPi-46 uptake measurements in and around the perianal fistula at baseline with clinical and MRI (and eventual endoscopy and pathology if available) parameters at baseline.

—

Countries

Netherlands

Outcome results

None listed